Latest Advances in Lung Cancer Research

Lung cancer cells can revert to an earlier developmental form, driving aggression and treatment resistance, offering new clues for personalized therapy.

A new lung cancer drug is making headlines. At the 2026 ASCO meeting, researchers shared exciting results for a drug called ivonescimab. In a large study, it lowered the risk of death by 34% for people with a hard-to-treat type of lung cancer.

For many years, small cell lung cancer treatments stayed mostly the same. Chemotherapy was the main option, and immunotherapy added in 2018 only helped a little. But now, new therapies are bringing real hope to patients and their families.

New data shows elisrasib provides strong, lasting tumor responses for advanced lung cancer patients, including those who failed previous KRAS-targeted treatments.

Researchers from Yale University looked at more than 28,000 older adults with early-stage non-small cell lung cancer. They found that Black patients were 8 to 9 percentage points less likely than White patients to receive curative treatment.

Severe viral infections, such as COVID-19, can increase the risk of lung cancer through immune cell changes, though vaccination significantly reduces these long-term harmful effects.

Small cell lung cancer (SCLC) is one of the deadliest forms of lung cancer. It makes up about 15% of all lung cancer cases and has a 5-year survival rate of only 7%. While newer treatments like immunotherapy have helped some patients, most still see only small benefits. New small cell lung cancer research published in Nature Communications may help change that.

Lung cancer kills more people than breast, colon, and cervical cancers combined. Yet it is the cancer we screen for the least. A new study in the Journal of the American Medical Association shows that universal lung cancer screening could change this.

Researchers used multi-omics (genetic, protein-related) data to find new molecular weaknesses in non-small cell lung cancer and offering fresh avenues for therapies.

The FDA has approved a new drug called Datroway (datopotamab deruxtecan) for patients with EGFR-positive non-small cell lung cancer (NSCLC) who have already tried targeted therapy and chemotherapy. This approval marks an important step forward in lung cancer treatment.

A new study provides the first genetic evidence that air pollution causes DNA mutations leading to lung cancer in people who have never smoked, helping explain why lung cancer rates are rising among never-smokers worldwide, particularly women and those of Asian ancestry.

Clinical cancer informatics research applying computational methods or digital health technologies to improve cancer care and patient outcomes.